Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer (Q50926016)

25 March 2018

title

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer (English)

1 reference

25 March 2018

C B Gilks

1 reference

25 March 2018

author name string

L Proctor

1 reference

25 March 2018

M Pradhan

1 reference

25 March 2018

S Leung

1 reference

25 March 2018

A Cheng

1 reference

25 March 2018

C H Lee

1 reference

25 March 2018

R A Soslow

1 reference

25 March 2018

A Talhouk

1 reference

25 March 2018

J M McAlpine

1 reference

25 March 2018

H E Danielsen

1 reference

25 March 2018

L N Hoang

1 reference

25 March 2018

language of work or name

English

0 references

publication date

21 June 2017

1 reference

25 March 2018

published in

Gynecologic Oncology

1 reference

25 March 2018

volume

146

1 reference

25 March 2018

issue

1 reference

25 March 2018

page(s)

596-602

1 reference

25 March 2018

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Prognostic parameters of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Integrated genomic characterization of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

A clinically applicable molecular-based classification for endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

DNA ploidy in endometrial cancer: unfinished business?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

The deoxyribonucleic acid content of carcinoma of the uterus: an assessment of its possible significance in relation to histopathology and clinical course, based on data from 165 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Clinical value of DNA content assessment in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Ploidy and S-phase fraction are correlated with lymphovascular space invasion that is predictive of outcomes in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Laminin-5 gamma2-chain expression and DNA ploidy as predictors of prognosis in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.06.020

10.1016/J.YGYNO.2017.06.020

7 January 2021

Identifiers

DOI

1 reference

25 March 2018

1 reference

25 March 2018